RE:RE:RE:Interesting Statsa major part of COGS would be related to royalties, so upfront investments for new drug intangible to replace legacy ones would be minor relative to the royalties of 15-20%+. and also remember many GUD drugs are small niche products, so can far outlive their patent life especially when grossing $5-20mn per drug.
I agree that FCF is better indicator, but its too hard to gauge what would be required as maintenance IP at this point. GUD needs to prove out organic growth with current portfolio where 60% are considered promoted / new launches
look at their overhead in argentina compared to sales of BGx 44% vs 22%, they are bloated in argentina, so need to restructure. a major part of depreciation was likely due to this, layoffs next?